

# World Journal of *Diabetes*

*World J Diabetes* 2024 March 15; 15(3): 308-574



## EDITORIAL

- 308 Unlocking new potential of clinical diagnosis with artificial intelligence: Finding new patterns of clinical and lab data  
*Dabla PK*
- 311 Acute worsening of microvascular complications of diabetes mellitus during rapid glycemic control: The pathobiology and therapeutic implications  
*Blaibel D, Fernandez CJ, Pappachan JM*
- 318 Periodontitis: An often-neglected complication of diabetes  
*Kudiyirickal MG, Pappachan JM*
- 326 Glucagon-like-peptide-1 receptor agonists and the management of type 2 diabetes-backwards and forwards  
*Horowitz M, Cai L, Islam MS*

## REVIEW

- 331 Practical guide: Glucagon-like peptide-1 and dual glucose-dependent insulintropic polypeptide and glucagon-like peptide-1 receptor agonists in diabetes mellitus  
*Alqifari SF, Alkomi O, Esmail A, Alkhawami K, Yousri S, Muqresh MA, Alharbi N, Khojah AA, Aljabri A, Allahham A, Prabakar K, Alshareef H, Aldhaeefi M, Alrasheed T, Alrabiah A, AlBishi LA*
- 348 Association of autoimmune thyroid disease with type 1 diabetes mellitus and its ultrasonic diagnosis and management  
*Wang J, Wan K, Chang X, Mao RF*
- 361 Metabolic disorders in prediabetes: From mechanisms to therapeutic management  
*Ping WX, Hu S, Su JQ, Ouyang SY*
- 378 Epigenetic modifications of placenta in women with gestational diabetes mellitus and their offspring  
*Yi Y, Wang T, Xu W, Zhang SH*

## MINIREVIEWS

- 392 Roles of fibroblast growth factors in the treatment of diabetes  
*Zhang CY, Yang M*

## ORIGINAL ARTICLE

## Case Control Study

- 403 Associations between Geriatric Nutrition Risk Index, bone mineral density and body composition in type 2 diabetes patients  
*Zhu XX, Yao KF, Huang HY, Wang LH*

- 418 Predictive value of angiotensin-like protein 8 in metabolic dysfunction-associated fatty liver disease and its progression: A case-control study

Gan LL, Xia C, Zhu X, Gao Y, Wu WC, Li Q, Li L, Dai Z, Yan YM

#### Retrospective Study

- 429 Myosteosis is associated with coronary artery calcification in patients with type 2 diabetes

Liu FP, Guo MJ, Yang Q, Li YY, Wang YG, Zhang M

- 440 Adherence to Advisory Committee on Immunization Practices in diabetes mellitus patients in Saudi Arabia: A multicenter retrospective study

Alqifari SF, Esmail AK, Alarifi DM, Alsuliman GY, Alhati MM, Mutlaq MR, Aldhaefi M, Alshuaibi SA, Amirthalingam P, Abdallah A, Wasel AS, Hamad HR, Alamin S, Atia TH, Alqahtani T

#### Observational Study

- 455 Evaluation of hybrid closed-loop insulin delivery system in type 1 diabetes in real-world clinical practice: One-year observational study

Eldib A, Dhaver S, Kibaa K, Atakov-Castillo A, Salah T, Al-Badri M, Khater A, McCarragher R, Elenani O, Toschi E, Hamdy O

- 463 Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience

Islam L, Jose D, Alkhalifah M, Blaibel D, Chandrabalan V, Pappachan JM

#### Clinical and Translational Research

- 475 Dietary fiber intake and its association with diabetic kidney disease in American adults with diabetes: A cross-sectional study

Jia XH, Wang SY, Sun AQ

#### Basic Study

- 488 MicroRNA-630 alleviates inflammatory reactions in rats with diabetic kidney disease by targeting toll-like receptor 4

Wu QS, Zheng DN, Ji C, Qian H, Jin J, He Q

- 502 Jianpi Gushen Huayu decoction ameliorated diabetic nephropathy through modulating metabolites in kidney, and inhibiting TLR4/NF- $\kappa$ B/NLRP3 and JNK/P38 pathways

Ma ZA, Wang LX, Zhang H, Li HZ, Dong L, Wang QH, Wang YS, Pan BC, Zhang SF, Cui HT, Lv SQ

- 519 Diabetes and high-glucose could upregulate the expression of receptor for activated C kinase 1 in retina

Tan J, Xiao A, Yang L, Tao YL, Shao Y, Zhou Q

- 530 Potential application of *Nardostachys Radix et Rhizoma*-Rhubarb for the treatment of diabetic kidney disease based on network pharmacology and cell culture experimental verification

Che MY, Yuan L, Min J, Xu DJ, Lu DD, Liu WJ, Wang KL, Wang YY, Nan Y

#### SYSTEMATIC REVIEWS

- 552 KCNQ1 rs2237895 gene polymorphism increases susceptibility to type 2 diabetes mellitus in Asian populations

Li DX, Yin LP, Song YQ, Shao NN, Zhu H, He CS, Sun JJ

**LETTER TO THE EDITOR**

- 565** Chiglitazar and Thiazolidinedione in patients with type 2 diabetes: Which is better?  
*Reddy KS, Gaur A, Varatharajan S, Morya AK*
- 568** Effects of vitamin family members on insulin resistance and diabetes complications  
*Chen HJ, Wang M, Zou DM, Liang GY, Yang SY*
- 572** Regulatory role of peroxynitrite in advanced glycation end products mediated diabetic cardiovascular complications  
*Bala A*

**ABOUT COVER**

Editorial Board Member of *World Journal of Diabetes*, Jun-Ling Shi, PhD, Professor, School of Life Sciences, Northwestern Polytechnical University, Xi'an 710072, Shaanxi Province, China. sjlshi2004@nwpu.edu.cn

**AIMS AND SCOPE**

The primary aim of *World Journal of Diabetes* (*WJD*, *World J Diabetes*) is to provide scholars and readers from various fields of diabetes with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

*WJD* mainly publishes articles reporting research results and findings obtained in the field of diabetes and covering a wide range of topics including risk factors for diabetes, diabetes complications, experimental diabetes mellitus, type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetes, diabetic angiopathies, diabetic cardiomyopathies, diabetic coma, diabetic ketoacidosis, diabetic nephropathies, diabetic neuropathies, Donohue syndrome, fetal macrosomia, and prediabetic state.

**INDEXING/ABSTRACTING**

The *WJD* is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports/Science Edition, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for *WJD* as 4.2; IF without journal self cites: 4.1; 5-year IF: 4.5; Journal Citation Indicator: 0.69; Ranking: 51 among 145 journals in endocrinology and metabolism; and Quartile category: Q2.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Production Editor: *Yu-Xi Chen*; Production Department Director: *Xu Guo*; Editorial Office Director: *Jia-Ru Fan*.

**NAME OF JOURNAL**

*World Journal of Diabetes*

**ISSN**

ISSN 1948-9358 (online)

**LAUNCH DATE**

June 15, 2010

**FREQUENCY**

Monthly

**EDITORS-IN-CHIEF**

Lu Cai, Md. Shahidul Islam, Michael Horowitz

**EDITORIAL BOARD MEMBERS**

<https://www.wjgnet.com/1948-9358/editorialboard.htm>

**PUBLICATION DATE**

March 15, 2024

**COPYRIGHT**

© 2024 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION ETHICS**

<https://www.wjgnet.com/bpg/GerInfo/288>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>

## Case Control Study

## Associations between Geriatric Nutrition Risk Index, bone mineral density and body composition in type 2 diabetes patients

Xiao-Xiao Zhu, Kai-Feng Yao, Hai-Yan Huang, Li-Hua Wang

**Specialty type:** Endocrinology and metabolism**Provenance and peer review:** Unsolicited article; Externally peer reviewed.**Peer-review model:** Single blind**Peer-review report's scientific quality classification**Grade A (Excellent): 0  
Grade B (Very good): 0  
Grade C (Good): C, C, C, C, C  
Grade D (Fair): 0  
Grade E (Poor): 0**P-Reviewer:** Chen GX, United States; Di Ciaula A, Italy; Gica N, Romania; Horowitz M, Australia; Yang MW, China**Received:** August 24, 2023**Peer-review started:** August 24, 2023**First decision:** November 21, 2023**Revised:** December 8, 2023**Accepted:** January 24, 2024**Article in press:** January 24, 2024**Published online:** March 15, 2024**Xiao-Xiao Zhu**, Department of Pediatrics, The Second Affiliated Hospital of Nantong University, First People's Hospital of Nantong City, Nantong 226001, Jiangsu Province, China**Kai-Feng Yao, Li-Hua Wang**, Department of Nursing, The Second Affiliated Hospital of Nantong University, First People's Hospital of Nantong City, Nantong 226001, Jiangsu Province, China**Hai-Yan Huang**, Department of Endocrinology, The Second Affiliated Hospital of Nantong University, First People's Hospital of Nantong City, Nantong 226001, Jiangsu Province, China**Corresponding author:** Li-Hua Wang, MNurs, Chief Nurse, Department of Nursing, The Second Affiliated Hospital of Nantong University, First People's Hospital of Nantong City, No. 666 Shengli Road, Nantong 226001, Jiangsu Province, China. [wlh512512@163.com](mailto:wlh512512@163.com)

## Abstract

## BACKGROUND

Type 2 diabetes mellitus (T2DM), a fast-growing issue in public health, is one of the most common chronic metabolic disorders in older individuals. Osteoporosis and sarcopenia are highly prevalent in T2DM patients and may result in fractures and disabilities. In people with T2DM, the association between nutrition, sarcopenia, and osteoporosis has rarely been explored.

## AIM

To evaluate the connections among nutrition, bone mineral density (BMD) and body composition in patients with T2DM.

## METHODS

We enrolled 689 patients with T2DM for this cross-sectional study. All patients underwent dual energy X-ray absorptiometry (DXA) examination and were categorized according to baseline Geriatric Nutritional Risk Index (GNRI) values calculated from serum albumin levels and body weight. The GNRI was used to evaluate nutritional status, and DXA was used to investigate BMD and body composition. Multivariate forward linear regression analysis was used to identify the factors associated with BMD and skeletal muscle mass index.

## RESULTS

Of the total patients, 394 were men and 295 were women. Compared with patients in tertile 1, those in tertile 3 who had a high GNRI tended to be younger and had lower HbA1c, higher BMD at all bone sites, and higher appendicular skeletal



muscle index (ASMI). These important trends persisted even when the patients were divided into younger and older subgroups. The GNRI was positively related to ASMI (men:  $r = 0.644$ ,  $P < 0.001$ ; women:  $r = 0.649$ ,  $P < 0.001$ ), total body fat (men:  $r = 0.453$ ,  $P < 0.001$ ; women:  $r = 0.557$ ,  $P < 0.001$ ), BMD at all bone sites, lumbar spine (L1-L4) BMD (men:  $r = 0.110$ ,  $P = 0.029$ ; women:  $r = 0.256$ ,  $P < 0.001$ ), FN-BMD (men:  $r = 0.293$ ,  $P < 0.001$ ; women:  $r = 0.273$ ,  $P < 0.001$ ), and hip BMD (men:  $r = 0.358$ ,  $P < 0.001$ ; women:  $r = 0.377$ ,  $P < 0.001$ ). After adjustment for other clinical parameters, the GNRI was still significantly associated with BMD at the lumbar spine and femoral neck. Additionally, a low lean mass index and higher  $\beta$ -collagen special sequence were associated with low BMD at all bone sites. Age was negatively correlated with ASMI, whereas weight was positively correlated with ASMI.

## CONCLUSION

Poor nutrition, as indicated by a low GNRI, was associated with low levels of ASMI and BMD at all bone sites in T2DM patients. Using the GNRI to evaluate nutritional status and using DXA to investigate body composition in patients with T2DM is of value in assessing bone health and physical performance.

**Key Words:** Geriatric Nutrition Risk Index; Bone mineral density; Skeletal muscle mass; Type 2 diabetes

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Osteoporosis and sarcopenia are highly prevalent in type 2 diabetes mellitus (T2DM) patients. In people with T2DM, the association between nutrition, sarcopenia, and osteoporosis has rarely been explored. We observed that poor nutrition, as indicated by a low Geriatric Nutritional Risk Index (GNRI), was associated with low levels of ASMI and bone mineral density at all bone sites in T2DM patients. Using the GNRI to evaluate nutritional status and using dual energy X-ray absorptiometry to investigate body composition in patients with T2DM is of value in assessing bone health and physical performance.

**Citation:** Zhu XX, Yao KF, Huang HY, Wang LH. Associations between Geriatric Nutrition Risk Index, bone mineral density and body composition in type 2 diabetes patients. *World J Diabetes* 2024; 15(3): 403-417

**URL:** <https://www.wjgnet.com/1948-9358/full/v15/i3/403.htm>

**DOI:** <https://dx.doi.org/10.4239/wjd.v15.i3.403>

## INTRODUCTION

Over the past few years, there has been a rise in the prevalence of osteoporosis and sarcopenia among the elderly population, leading to physical impairment, diminished quality of life and even death of patients[1,2]. Type 2 diabetes mellitus (T2DM), a rapidly growing public health problem, is one of the most common chronic metabolic disorders in older individuals[3]. For patients with T2DM, osteoporosis is one of the possible long-term complications[4]. Sarcopenia, or loss of muscle mass and function, is a major cause of disability in diabetes[5]. Therefore, it is imperative to identify early sarcopenia, osteoporosis and their risk factors in older individuals with T2DM. Subsequently, suitable measures should be taken to avert and manage this ailment.

As a multifactorial systemic disease, many factors contribute to sarcopenia, such as age, sex, body mass index (BMI), duration of diabetes, glycemic control, nutritional status, and lifestyle[6-8]. Sarcopenia is commonly believed to be a decline in skeletal muscle mass and reduced muscle function that occurs with age. In sarcopenia research, the Asia Working Group for Sarcopenia suggests the utilization of the skeletal muscle index (SMI). This index is calculated by dividing the appendicular skeletal muscle mass (ASMM) by the square of height, providing an adjusted measurement of muscle mass[9]. The factors associated with osteoporosis in T2DM include age, sex, BMI, serum vitamin D concentrations, lifestyle factors, duration of diabetes[10], and nutritional risk[11]. Since there are several common factors in osteoporosis and sarcopenia, many studies of the association between osteoporosis and skeletal muscle mass have been reported. The connection between low muscle mass and osteoporosis in patients with T2DM remains uncertain.

Malnutrition is frequently found in elderly individuals. Older adults with T2DM may face an increased risk of undernutrition due to excessively strict dietary habits aimed at managing blood sugar levels[12]. Various tools have been developed to assess malnutrition status, including the Malnutrition Screening Tool[13], Malnutrition Universal Screening Tool[14], Mini Nutritional Assessment Short Form[15], Nutrition Risk Score 2002[16], and Geriatric Nutritional Risk Index (GNRI)[17]. The GNRI has been utilized as a convenient and accessible method among these instruments for assessing outcomes, relying on serum albumin levels and the ratio of real body weight to ideal body weight.

The relationship between nutritional status and bone mass has been observed in different populations, such as individuals with chronic obstructive pulmonary disease[18], rheumatoid arthritis[19,20], and end-stage renal disease[21]. In people with T2DM, nutrition, sarcopenia, and osteoporosis are rarely explored. Therefore, in this study, we investigated associations between bone mineral density (BMD), the GNRI and body composition in patients with T2DM.

## MATERIALS AND METHODS

### Study design and participants

We conducted a retrospective cross-sectional study among T2DM patients admitted to the Department of Endocrinology, The Second Affiliated Hospital of Nantong University, between January 1, 2020, and March 1, 2022.

### Patients

The main inclusion criterion in this study was T2DM. T2DM was defined as a fasting blood glucose level of  $> 7.0$  mmol/L and/or a 2-h postprandial blood glucose level  $> 11.1$  mmol/L in an oral glucose tolerance test, in accordance with the 1999 World Health Organization T2DM diagnosis and classification criteria. The patients were excluded based on the following criteria: (1) Malignant tumor and severe heart, cerebral, liver or kidney diseases; (2) pituitary, thyroid, parathyroid and adrenal diseases; (3) treatment with glucocorticoids or sex hormones in the past 6 mo; (4) concomitantly taking drugs affecting bone metabolism, such as calcium, vitamin D and bisphosphonates; and (5) unavailability of complete data on relevant variables and assessments. This study was approved by the ethics committee of The Second Affiliated Hospital of Nantong University and was in line with the Helsinki Declaration. The number for ethics approval was 2021KT063.

### Data collection

**Collection of demographic, medical, and laboratory data:** All demographic information and relevant medical histories of the participants were recorded from their medical records. Demographic data included age, sex, height, weight and BMI. Body weight and height were measured with the patient lightly clothed and without shoes. BMI ( $\text{kg}/\text{m}^2$ ) was calculated as body weight in kilograms divided by height in meters squared. Medical history included diabetes duration and history of hypertension. The duration of diabetes was calculated by months from the time that the patient was diagnosed with T2DM in their medical records to the date we took blood tests. We also collected the glucose-lowering therapy status among participants. Glucose-lowering therapies were categorized as lifestyle alone and drug therapy. Hypoglycemic agents included insulin, insulin secretagogues, insulin sensitizers, metformin, AGIs ( $\alpha$ -glucosidase inhibitors), DPP-4Is (dipeptidyl peptidase-4 inhibitors), SGLT-2Is (sodium-glucose cotransporter-2 inhibitors) and GLP-1RAs (glucagon-like peptide-1 receptor agonists).

For laboratory data collection, the nurses in the ward took blood samples from the antecubital vein in the early morning hours after overnight fasting (at least 8 h). Triglycerides (TGs; colorimetric method), total cholesterol (TC; cholesterol oxidase method), low-density lipoprotein cholesterol (LDL-C; selective melting method) and high-density lipoprotein cholesterol (HDL-C; enzyme modification method) were measured by an automatic biochemical instrument (Model 7600, Hitachi). The level of HbA1c was assessed by ion exchange high-performance liquid chromatography. The levels of bone metabolism markers, including osteocalcin (OS),  $\beta$ -collagen special sequence ( $\beta$ -CTX) and total type I procollagen N-terminal extension peptide (TP1NP). Additionally, other biochemical markers, such as serum creatinine (Cr), uric acid (UA), albumin and total bilirubin (TBil), were measured according to standard methodology.

**BMD and body composition measurements:** BMD and body composition were measured using dual energy X-ray absorptiometry (DXA; Hologic-Discovery Wi, S/N86856). All of the patients were scanned, and calculations were performed by professionals in the corresponding medical and technical departments. According to the instrument manual, all operations were carried out in the standard mode: The patient lay flat and was scanned from head to feet. The measured indices included lumbar spine (L1-L4) BMD (LS-BMD), femoral neck BMD (FN-BMD), hip BMD, total (whole-body) BMD, total body fat, the android/gynoid ratio, fat mass index, lean mass index and appendicular SMI (ASMI). BMD ( $\text{g}/\text{cm}^2$ ) was calculated using the following formula: Bone mineral content ( $\text{g}$ )/area ( $\text{cm}^2$ ); ASMI was calculated by limb skeletal muscle mass: ASMM ( $\text{kg}$ )/height<sup>2</sup> ( $\text{m}^2$ ); lean mass index was calculated using the following formula: Lean mass ( $\text{kg}$ )/height<sup>2</sup> ( $\text{m}^2$ ); and fat mass index was calculated using the following formula: Fat mass ( $\text{kg}$ )/height<sup>2</sup> ( $\text{m}^2$ ).

### Calculation of the GNRI


Based on the serum albumin level and baseline body weight, the GNRI is calculated as follows:  $\text{GNRI} = [1.489 \text{ albumin (g/L)} + (\text{weight/ideal weight})]$ . Ideal weight can be further calculated by the following equations: Men: Ideal weight = height (cm) - 100 - [(height - 150)/4]; Women: Ideal weight = height (cm) - 100 - [(height - 150)/2.5].

### Statistical analysis

The patients were classified by GNRI tertiles with cutoff values of  $< 101.85$ ,  $101.85$  to  $109.52$ , and  $> 109.52$ . A descriptive analysis of the data was performed based on the type of data, including the mean and standard deviation, and frequency and percentage. The trends of continuous data and categorical data were detected using one-way ANOVA with linear polynomial contrasts, Kruskal-Wallis tests, and Chi-squared tests with linear-by-linear associations. Furthermore, we generated scatter plots using GraphPad Prism to show the correlation between the GNRI and BMD, ASMI, and total body fat (T-FAT). The factors associated with BMD and ASMI were identified using multiple stepwise linear regression analyses.

For the statistical analysis, we employed IBM SPSS Statistics (25.0) and GraphPad Prism (9.0). Statistical significance was determined using a  $P$  value less than 0.05. Normally distributed values are given as the mean  $\pm$  SD, skewed distributed values are given as the median (25% and 75% interquartiles), and categorical variables are given as frequency (percentage).





**Figure 1** Scatter diagrams showing the correlation between Geriatric Nutritional Risk Index, bone mineral density, total body fat and appendicular skeletal muscle index. A: Lumbar spine (L1-L4) bone mineral density (BMD); B: Femoral neck BMD; C: Hip BMD; D: Appendicular skeletal muscle index; E: Total (whole-body) BMD. BMD: Bone mineral density; GNRI: Geriatric Nutritional Risk Index; LS-BMD: Lumbar spine (L1-L4) bone mineral density; FN-BMD: Femoral neck bone mineral density; H-BMD: Hip bone mineral density; T-FAT: Total body fat.

## RESULTS

In this study, we enrolled 689 patients (57.2% men and 42.8% women), with a mean age of  $55.59 \pm 10.88$  years.

### Patient characteristics

Table 1 shows comparisons of the characteristics of the patients classified by GNRI tertiles. Compared with patients in tertile 1, those in tertile 3 tended to be younger, had lower HbA1c and  $\beta$ -CTX, and had higher BMI, BMD, total body fat, android/gynoid ratio, fat mass index, lean mass index, ASMI, albumin, UA, TG, TC and TBil. These important trends persisted even when the patients were divided into younger and older subgroups (Tables 2-4).

### Associations between GNRI, BMD, T-FAT and ASMI

Figure 1 shows the correlation between GNRI, BMD, T-FAT and ASMI in T2DM patients; the average BMD at the lumbar spine, femur neck and total hip in men was higher than that in women (1.00 vs 0.92, 0.81 vs 0.73, 0.94 vs 0.86, respectively, and all  $P < 0.001$ ); the GNRI was found to be positively and significantly associated with ASMI, T-FAT and BMD at all

**Table 1 Comparison of baseline characteristics among type 2 diabetes mellitus patients stratified by tertiles of the Geriatric Nutritional Risk Index**

Characteristics	Total (n = 689)	GNRI tertile 1 (n = 230)	GNRI tertile 2 (n = 230)	GNRI tertile 3 (n = 229)	F/H/ $\chi^2$	P value
Women [n (%)]	295 (42.8)	109 (47.4)	96 (41.7)	90 (39.3)	3.065	0.080
Age (yr)	55.59 ± 10.88	58.02 ± 10.49	56.00 ± 10.84	52.74 ± 10.69	28.071	< 0.001
Height (cm)	166.89 ± 8.24	165.25 ± 7.88	167.10 ± 8.52	168.33 ± 8.06	16.410	< 0.001
Weight (kg)	70.00 (62.00-80.00)	62.00 (56.00-69.00)	71.00 (64.75-78.85)	80.00 (72.75-90.00)	16.636	< 0.001
Diabetes duration (yr)	7.33 ± 6.20	8.96 ± 6.42	7.58 ± 6.44	5.45 ± 5.15	38.741	< 0.001
BMI (kg/m <sup>2</sup> )	25.39 (23.23-27.78)	22.92 (21.31-24.49)	25.53 (24.20-26.93)	28.28 (26.62-30.47)	19.284	< 0.001
SBP (mmHg)	133.84 ± 15.34	132.96 ± 16.80	133.89 ± 15.98	134.67 ± 12.98	1.420	0.234
DBP (mmHg)	81.00 ± 9.88	79.44 ± 10.19	80.76 ± 9.50	82.79 ± 9.70	13.343	< 0.001
Hypertension [n (%)]	333 (48.3)	112 (48.7)	117 (50.9)	104 (45.4)	0.492	0.483
GNRI (score)	105.61 (99.64-112.01)	97.09 (93.02-99.66)	105.62 (103.73-107.68)	114.25 (112.01-119.37)	27.818	< 0.001
<b>Glucose-lowering therapies [n (%)]</b>						
Lifestyle alone	121 (17.6)	31 (13.5)	36 (15.7)	54 (23.6)	8.071	0.004
Insulin treatments	248 (36.0)	102 (44.3)	89 (38.7)	57 (24.9)	18.817	< 0.001
Insulin secretagogues	222 (32.2)	83 (36.1)	78 (33.9)	61 (26.6)	4.681	0.030
Insulin sensitizers	79 (11.5)	25 (10.9)	28 (12.2)	26 (11.4)	0.027	0.870
Metformin	322 (46.7)	88 (38.3)	110 (47.8)	124 (54.1)	11.622	< 0.001
AGIs	105 (15.2)	23 (10.0)	33 (14.3)	49 (21.4)	11.519	< 0.001
DPP-4Is	57 (8.3)	18 (7.8)	23 (10.0)	16 (7.0)	0.105	0.745
SGLT-2Is	93 (13.5)	28 (12.2)	35 (15.2)	30 (13.1)	0.085	0.771
GLP-1RAs	41 (6.0)	3 (1.3)	14 (6.1)	24 (10.5)	17.240	< 0.001
Statins	122 (17.7)	37 (16.1)	45 (19.6)	40 (17.5)	0.151	0.698
<b>Laboratory findings</b>						
HbA1c (%)	8.99 ± 1.85	9.50 ± 2.02	8.92 ± 1.63	8.53 ± 1.75	33.073	< 0.001
Albumin (g/L)	38.50 (36.20-41.30)	35.90 (33.88-37.63)	38.60 (37.00-40.60)	41.70 (39.45-44.00)	17.954	< 0.001
Cr (μmol/L)	58.51 ± 21.32	58.22 ± 25.22	57.85 ± 21.58	59.46 ± 16.26	0.386	0.535
UA (μmol/L)	312.68 ± 99.25	279.47 ± 103.09	314.02 ± 89.46	344.68 ± 94.19	53.222	< 0.001
TG (mmol/L)	1.89 (1.18-3.11)	1.46 (0.98-2.33)	1.81 (1.15-2.83)	2.38 (1.58-3.98)	7.626	< 0.001
TC (mmol/L)	4.41 ± 1.06	4.29 ± 1.01	4.33 ± 0.98	4.62 ± 1.15	10.890	0.001
HDL-C (mmol/L)	1.14 ± 0.27	1.15 ± 0.28	1.15 ± 0.25	1.10 ± 0.27	3.679	0.056
LDL-C (mmol/L)	2.81 ± 0.87	2.80 ± 0.88	2.80 ± 0.82	2.84 ± 0.91	0.309	0.578
TBil (μmol/L)	11.21 ± 4.71	10.25 ± 4.60	11.43 ± 4.68	11.95 ± 4.70	15.213	< 0.001
OS (ng/mL)	11.85 ± 3.99	12.06 ± 4.26	11.88 ± 3.89	11.60 ± 3.82	1.508	0.220
β-CITX (ng/mL)	0.45 ± 0.22	0.51 ± 0.25	0.44 ± 0.21	0.41 ± 0.19	25.645	< 0.001
TP1NP (ng/mL)	40.73 ± 14.53	41.00 ± 14.00	40.74 ± 14.66	40.45 ± 14.98	0.165	0.685
<b>DXA parameters (g/cm<sup>2</sup>)</b>						
LS-BMD	0.97 ± 0.16	0.92 ± 0.14	0.99 ± 0.17	0.99 ± 0.15	22.118	< 0.001
FN-BMD	0.77 ± 0.12	0.73 ± 0.12	0.79 ± 0.13	0.81 ± 0.11	53.333	< 0.001
H-BMD	0.91 ± 0.13	0.85 ± 0.12	0.91 ± 0.13	0.95 ± 0.12	83.980	< 0.001

T-BMD	1.10 ± 0.12	1.07 ± 0.12	1.10 ± 0.12	1.12 ± 0.11	21.875	< 0.001
<b>Body composition</b>						
Total body fat (%)	31.03 ± 6.56	29.03 ± 6.55	30.80 ± 5.83	33.26 ± 6.62	51.017	< 0.001
Android/gynoid ratio	1.31 ± 0.22	1.23 ± 0.22	1.33 ± 0.21	1.36 ± 0.20	49.682	< 0.001
Fat mass index (kg/m <sup>2</sup> )	7.53 (6.20-9.09)	6.33 (5.08-7.53)	7.54 (6.44-8.74)	8.91 (7.51-10.75)	13.010	< 0.001
Lean mass index (kg/m <sup>2</sup> )	16.95 (15.53-18.54)	15.66 (14.44-16.83)	17.11 (15.92-18.39)	18.60 (16.99-19.90)	14.055	< 0.001
ASMI (kg/m <sup>2</sup> )	7.09 ± 1.17	6.38 ± 0.91	7.09 ± 0.97	7.79 ± 1.1	218.066	< 0.001

BMI: Body mass index; SBP: Systolic/diastolic blood pressure; DBP: Diastolic blood pressure; GNRI: Geriatric nutritional risk index; AGIs:  $\alpha$ -glucosidase inhibitors; DPP-4Is: Dipeptidyl peptidase-4 inhibitors; SGLT-2Is: Sodium-glucose cotransporter-2 inhibitors; GLP-1RAs: Glucagon-like peptide-1 receptor agonists; Cr: Creatinine; UA: Uric acid; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TBil: Total bilirubin; OS: Osteocalcin;  $\beta$ -CTX:  $\beta$ -collagen special sequence; TP1NP: Total type I procollagen N-terminal extension peptide; DXA: Dual energy X-ray absorptiometry; LS-BMD: Lumbar spine (L1-L4) bone mineral density; FN-BMD: Femoral neck bone mineral density; H-BMD: Hip bone mineral density; T-BMD: Total (whole-body) bone mineral density; ASMI: Appendicular skeletal muscle index.

bone sites in men and women; Table 5 shows multiple linear regression models displaying associations of the GNRI with BMD; the fully adjusted Model 3 further adjusted for HbA1c, OS,  $\beta$ -CTX, TP1NP, albumin, Cr, UA, TG, TC, HDL-C, LDL-C, TBil, and the GNRI was significantly and positively associated with LS-BMD ( $b = 0.040$ ,  $t = 2.492$ ,  $P = 0.013$ ,  $R^2 = 0.197$ ) and FN-BMD ( $b = 0.027$ ,  $t = 2.345$ ,  $P = 0.019$ ,  $R^2 = 0.341$ ).

### Multivariate forward linear regression analysis of the determinants of BMD and ASMI

Table 6 shows the determinants of BMD using multivariate stepwise linear regression analysis after adjusting for age, sex, height, weight, diabetes duration, hypertension, systolic/diastolic blood pressure (SBP), diastolic blood pressure (DBP), GNRI, BMI, HbA1c, OS,  $\beta$ -CTX, TP1NP, albumin, Cr, UA, TG, TC, HDL-C, LDL-C, TBil, ASMI, total body fat, android/gynoid ratio, fat mass index and lean mass index; the lean mass index was positively correlated with BMD at all bone sites; age, diabetes duration and  $\beta$ -CTX were negatively correlated with BMD at all bone sites; height and Cr were positively correlated with lumbar spine BMD, whereas albumin and ASMI were negatively correlated with lumbar spine BMD; albumin and the android/gynoid ratio were negatively correlated with femoral neck BMD, whereas height was positively correlated with femoral neck BMD; weight was positively correlated with total hip BMD, whereas the android/gynoid ratio was negatively correlated with total hip BMD.

Table 7 shows the determinants of ASMI using multivariate forward linear regression analysis after adjusting for age, sex, height, weight, diabetes duration, hypertension, SBP, DBP, GNRI, BMI, HbA1c, OS,  $\beta$ -CTX, TP1NP, albumin, Cr, UA, TG, TC, HDL-C, LDL-C and TBil; in men, age, diabetes duration and HbA1c were negatively correlated with ASMI, whereas weight and BMI were positively correlated with ASMI; in women, weight and OS were positively correlated with ASMI, whereas age, height, TBil and  $\beta$ -CTX were negatively correlated with ASMI.

## DISCUSSION

This study investigated associations among GNRI, BMD, and ASMI in T2DM patients. In this research, we discovered that proper nutrition, as denoted by a high GNRI, was linked to a lower HbA1c, higher BMD at all bone sites, higher lean mass index and higher ASMI. Based on prior research, this study utilized the GNRI and found that the GNRI was positively related to ASMI and BMD at all bone sites in T2DM patients. Additionally, a low lean mass index and higher  $\beta$ -CTX were associated with low BMD at all bone sites. Age was negatively correlated with ASMI, whereas weight was positively correlated with ASMI.

Despite the appropriate consumption, the nutrition of patients with T2DM was significantly impacted[22]. Diabetes speeds up the decline of muscle power, quality and serum albumin, highlighting the importance of maintaining a proper balance of protein and energy in one's diet. The current investigation demonstrated that a decreased GNRI posed a notable hazard for diminished BMD and ASMI among individuals with T2DM. This finding is consistent with previous studies[23]. Studies have demonstrated that the GNRI can be applied as a convenient and reliable indicator of the BMD and ASMI conditions of patients with chronic hepatitis C[24], postmenopausal women who have undergone total thyroidectomy[25] and patients receiving hemodialysis[26]. Therefore, the GNRI might be a convenient and reliable indicator of BMD and ASMI status in patients with T2DM. As albumin level reflects protein status and is a major component of the GNRI, the effect of protein on bone and muscle may help to explain the associations between GNRI, BMD and ASMI.

The second important finding of this study is that a low GNRI was associated with a higher HbA1c. This indicates that the presence of malnutrition is not conducive to blood sugar control. In addition to drug therapy, the basic treatment regimen for type 2 diabetes patients is diet restriction and exercise to achieve the goal of controlling blood sugar. Malnutrition can result if there is no strict and regular diet strategy. A previous study has proven that hyperglycemia contributes to the accelerated decline in muscle mass among patients with T2DM[27]. Higher HbA1c levels may lead to

**Table 2 Comparison of baseline characteristics among type 2 diabetes mellitus patients stratified by the tertiles of age**

Characteristics	Total (n = 689)	Younger <sup>1</sup> (n = 219)	Older <sup>2</sup> (n = 470)	$\chi^2/t/z$	P value
Women [n (%)]	295 (42.8)	111 (50.7)	184 (39.1)	8.120	0.004
Age (yr)	55.59 ± 10.88	43.71 ± 7.23	61.12 ± 7.25	-29.374	< 0.001
Height (cm)	166.89 ± 8.24	167.33 ± 8.55	166.69 ± 8.1	0.951	0.342
Weight (kg)	70.00 (62.00-80.00)	71.00 (62.00-82.00)	70.00 (62.00-80.00)	-1.178	0.239
Diabetes duration (yr)	7.33 ± 6.20	4.44 ± 3.82	8.68 ± 6.62	-10.603	< 0.001
BMI (kg/m <sup>2</sup> )	25.39 (23.23-27.78)	25.42 (23.11-28.34)	25.39 (23.32-27.55)	-1.001	0.317
SBP (mmHg)	133.84 ± 15.34	128.84 ± 13.78	136.16 ± 15.49	-5.977	< 0.001
DBP (mmHg)	81.00 ± 9.88	81.74 ± 10.15	80.65 ± 9.75	1.342	0.180
Hypertension [n (%)]	333 (48.3)	66 (30.1)	267 (56.8)	42.556	< 0.001
GNRI (score)	105.61 (99.64-112.01)	107.2 (101.18-113.56)	105.09 (98.93-110.98)	-2.880	0.004
<b>Glucose-lowering therapies</b>					
Lifestyle alone [n (%)]	121 (17.6)	58 (26.5)	63 (13.4)	17.653	< 0.001
Insulin treatments [n (%)]	248 (36.0)	73 (33.3)	175 (37.2)	0.987	0.321
Insulin secretagogues [n (%)]	222 (32.2)	44 (20.1)	178 (37.9)	21.627	< 0.001
Insulin sensitizers [n (%)]	79 (11.5)	20 (9.1)	59 (12.6)	1.722	1.189
Metformin [n (%)]	322 (46.7)	92 (42.0)	230 (48.9)	2.880	0.090
AGIs [n (%)]	105 (15.2)	29 (13.2)	76 (16.2)	0.992	0.319
DPP-4Is [n (%)]	57 (8.3)	19 (8.7)	38 (8.1)	0.069	0.793
SGLT-2Is [n (%)]	93 (13.5)	26 (11.9)	67 (14.3)	0.727	0.394
GLP-1RAs [n (%)]	41 (6.0)	15 (6.8)	26 (5.5)	0.463	0.496
Statins [n (%)]	122 (17.7)	38 (17.4)	84 (17.9)	0.028	0.868
<b>Laboratory findings</b>					
HbA1c (%)	8.99 ± 1.85	8.99 ± 1.9	8.98 ± 1.82	0.075	0.941
Albumin (g/L)	38.50 (36.20-41.30)	39.00 (36.8-41.6)	38.25 (35.8-41)	-2.470	0.014
Cr (μmol/L)	58.51 ± 21.32	52.09 ± 12.75	61.5 ± 23.74	-6.750	< 0.001
UA (μmol/L)	312.68 ± 99.25	317.68 ± 112.65	310.35 ± 92.39	0.903	0.367
TG (mmol/L)	1.89 (1.18-3.11)	1.99 (1.28-3.41)	1.78 (1.15-2.87)	-1.940	0.052
TC (mmol/L)	4.41 ± 1.06	4.5 ± 1.09	4.37 ± 1.04	1.475	0.141
HDL-C (mmol/L)	1.14 ± 0.27	1.09 ± 0.25	1.16 ± 0.27	-3.049	0.002
LDL-C (mmol/L)	2.81 ± 0.87	2.85 ± 0.87	2.79 ± 0.87	0.803	0.422
TBil (μmol/L)	11.21 ± 4.71	10.99 ± 4.28	11.31 ± 4.89	-0.836	0.404
OS (ng/mL)	11.85 ± 3.99	11.93 ± 3.43	11.81 ± 4.23	0.409	0.683
β-Ctx (ng/mL)	0.45 ± 0.22	0.47 ± 0.21	0.45 ± 0.23	1.137	0.256
TPINP (ng/mL)	40.73 ± 14.53	41.58 ± 13.84	40.34 ± 14.84	1.044	0.297
<b>DXA parameters (g/cm<sup>2</sup>)</b>					
LS-BMD	0.97 ± 0.16	1.00 ± 0.14	0.95 ± 0.16	4.126	< 0.001
FN-BMD	0.77 ± 0.12	0.82 ± 0.12	0.75 ± 0.12	6.360	< 0.001
H-BMD	0.91 ± 0.13	0.94 ± 0.12	0.89 ± 0.13	5.441	< 0.001
T-BMD	1.10 ± 0.12	1.13 ± 0.1	1.08 ± 0.12	4.643	< 0.001
<b>Body composition</b>					
Total body fat (%)	31.03 ± 6.56	31.76 ± 6.25	30.69 ± 6.68	2.001	0.046

Android/gynoid ratio	1.31 ± 0.22	1.3 ± 0.22	1.31 ± 0.21	-0.107	0.915
Fat mass index (kg/m <sup>2</sup> )	7.53 (6.20-9.09)	7.94 (6.55-9.26)	7.32 (6.17-8.99)	-2.621	0.009
Lean mass index (kg/m <sup>2</sup> )	16.95 (15.53-18.54)	17.01 (15.45-18.66)	16.94 (15.56-18.51)	-0.952	0.341
ASMI (kg/m <sup>2</sup> )	7.09 ± 1.17	7.23 ± 1.31	7.02 ± 1.09	2.026	0.043

<sup>1</sup>Men aged < 50 years and women aged < 55 years.

<sup>2</sup>Men aged ≥ 50 years and postmenopausal women aged ≥ 55 years.

BMI: Body mass index; SBP: Systolic/diastolic blood pressure; DBP: Diastolic blood pressure; GNRI: Geriatric nutritional risk index; AGIs:  $\alpha$ -glucosidase inhibitors; DPP-4Is: Dipeptidyl peptidase-4 inhibitors; SGLT-2Is: Sodium-glucose cotransporter-2 inhibitors; GLP-1RAs: Glucagon-like peptide-1 receptor agonists; Cr: Creatinine; UA: Uric acid; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TBil: Total bilirubin; OS: Osteocalcin;  $\beta$ -CTX:  $\beta$ -collagen special sequence; TP1NP: Total type I procollagen N-terminal extension peptide; DXA: Dual energy X-ray absorptiometry; LS-BMD: Lumbar spine (L1-L4) bone mineral density; FN-BMD: Femoral neck bone mineral density; H-BMD: Hip bone mineral density; T-BMD: Total (whole-body) bone mineral density; ASMI: Appendicular skeletal muscle index.

**Table 3 Comparison of baseline characteristics among younger type 2 diabetes mellitus patients**

Characteristics	Total (n = 219)	GNRI tertile 1 (n = 63)	GNRI tertile 2 (n = 68)	GNRI tertile 3 (n = 88)	<i>F</i> / <i>H</i> / $\chi^2$	<i>P</i> value
Women [ <i>n</i> (%)]	111 (50.7)	40 (63.5)	33 (48.5)	38 (43.5)	5.786	0.016
Age (yr)	43.71 ± 7.23	45.87 ± 6.84	43.04 ± 6.45	42.67 ± 7.80	6.880	0.009
Height (cm)	167.33 ± 8.55	164.57 ± 8.13	167.1 ± 8.49	169.48 ± 8.38	12.759	< 0.001
Weight (kg)	71.00 (62.00-82.00)	60.00 (56.00-66.70)	70.00 (64.00-76.85)	83.05 (74.25-93.20)	10.568	< 0.001
Diabetes duration (yr)	4.44 ± 3.82	5.84 ± 3.91	4.82 ± 4.03	3.15 ± 3.14	20.524	< 0.001
BMI (kg/m <sup>2</sup> )	25.42 (23.11-28.34)	22.72 (21.10-23.88)	25.32 (23.84-26.57)	28.60 (26.97-31.73)	11.641	< 0.001
SBP (mmHg)	128.84 ± 13.78	126.62 ± 13.78	123.6 ± 13.08	134.49 ± 12.31	16.237	< 0.001
DBP (mmHg)	81.74 ± 10.15	80.22 ± 10.41	77.99 ± 7.75	85.72 ± 10.30	14.496	< 0.001
Hypertension [ <i>n</i> (%)]	66 (30.1)	17 (27.0)	21 (30.9)	28 (31.8)	0.383	0.536
GNRI (score)	107.2 (101.18-113.56)	97.28 (92.85-99.92)	105.69 (104.20-107.71)	114.90 (112.15-120.21)	15.551	< 0.001
<b>Glucose-lowering therapies [<i>n</i> (%)]</b>						
Lifestyle alone	58 (26.5)	14 (22.2)	12 (17.6)	32 (36.4)	4.469	0.035
Insulin treatments	73 (33.3)	28 (44.4)	30 (44.1)	15 (17.0)	13.761	< 0.001
Insulin secretagogues	44 (20.1)	12 (19.0)	18 (26.5)	14 (15.9)	0.382	0.536
Insulin sensitizers	20 (9.1)	6 (9.5)	6 (8.8)	8 (9.1)	0.006	0.936
Metformin	92 (42.0)	20 (31.7)	31 (45.6)	41 (46.6)	2.617	0.106
AGIs	29 (13.2)	6 (9.5)	7 (10.3)	16 (18.2)	11.519	< 0.001
DPP-4Is	19 (8.7)	4 (6.3)	9 (13.2)	6 (6.8)	0.002	0.961
SGLT-2Is	26 (11.9)	11 (17.5)	8 (11.8)	7 (8.0)	3.118	0.077
GLP-1RAs	15 (6.8)	0 (0.0)	5 (7.4)	10 (11.4)	7.234	0.007
Statins	38 (17.4)	12 (19.0)	12 (17.6)	14 (15.9)	0.256	0.613
<b>Laboratory findings</b>						
HbA1c (%)	8.99 ± 1.9	9.58 ± 2.26	9.07 ± 1.66	8.52 ± 1.69	12.151	0.001
Albumin (g/L)	39.00 (36.8-41.6)	36.20 (34.60-37.90)	39.15 (37.20-40.75)	41.60 (39.00-44.23)	9.497	< 0.001
Cr ( $\mu$ mol/L)	52.09 ± 12.75	48.4 ± 13.54	51.31 ± 10.27	55.35 ± 13.2	11.693	0.001
UA ( $\mu$ mol/L)	317.68 ± 112.65	270.22 ± 140.24	313.84 ± 90.09	354.62 ± 92.24	22.682	< 0.001
TG (mmol/L)	1.99 (1.28-3.41)	1.50 (0.98-2.02)	2.03 (1.12-3.52)	2.46 (1.84-4.42)	5.412	< 0.001



TC (mmol/L)	4.5 ± 1.09	4.37 ± 0.94	4.3 ± 0.85	4.75 ± 1.30	5.389	0.021
HDL-C (mmol/L)	1.09 ± 0.25	1.15 ± 0.26	1.08 ± 0.21	1.06 ± 0.26	4.644	0.032
LDL-C (mmol/L)	2.85 ± 0.87	2.92 ± 0.91	2.86 ± 0.79	2.79 ± 0.92	0.850	0.358
TBil (μmol/L)	10.99 ± 4.28	9.78 ± 3.67	11.11 ± 4.15	11.76 ± 4.63	7.855	0.006
OS (ng/mL)	11.93 ± 3.43	12.05 ± 3.14	11.77 ± 3.07	11.98 ± 3.90	0.008	0.931
β-CTX (ng/mL)	0.47 ± 0.21	0.53 ± 0.24	0.45 ± 0.19	0.44 ± 0.20	5.436	0.021
TP1NP (ng/mL)	41.58 ± 13.84	41.95 ± 11.58	40.21 ± 13.02	42.37 ± 15.87	0.075	0.784
<b>DXA parameters (g/cm<sup>2</sup>)</b>						
LS-BMD	1.00 ± 0.14	0.96 ± 0.14	1.01 ± 0.13	1.02 ± 0.15	7.426	0.007
FN-BMD	0.82 ± 0.12	0.77 ± 0.11	0.82 ± 0.12	0.85 ± 0.11	18.433	< 0.001
H-BMD	0.94 ± 0.12	0.88 ± 0.11	0.94 ± 0.11	0.99 ± 0.11	34.357	< 0.001
T-BMD	1.13 ± 0.1	1.1 ± 0.11	1.12 ± 0.09	1.15 ± 0.10	8.681	0.004
<b>Body composition</b>						
Total body fat (%)	31.76 ± 6.25	29.85 ± 5.69	31.24 ± 5.90	33.53 ± 6.49	13.922	< 0.001
Android/gynoid ratio	1.3 ± 0.22	1.21 ± 0.22	1.31 ± 0.19	1.37 ± 0.21	22.631	< 0.001
Fat mass index (kg/m <sup>2</sup> )	7.94 (6.55-9.26)	6.56 (5.61-7.63)	7.89 (6.52-8.88)	9.13 (7.71-11.21)	7.905	< 0.001
Lean mass index (kg/m <sup>2</sup> )	17.01 (15.45-18.66)	15.25 (14.14-16.62)	16.93 (15.82-18.37)	18.65 (17.26-20.34)	9.380	< 0.001
ASMI (kg/m <sup>2</sup> )	7.23 ± 1.31	6.23 ± 0.90	7.09 ± 1.00	8.04 ± 1.24	105.442	< 0.001

BMI: Body mass index; SBP: Systolic/diastolic blood pressure; DBP: Diastolic blood pressure; GNRI: Geriatric nutritional risk index; AGIs:  $\alpha$ -glucosidase inhibitors; DPP-4Is: Dipeptidyl peptidase-4 inhibitors; SGLT-2Is: Sodium-glucose cotransporter-2 inhibitors; GLP-1RAs: Glucagon-like peptide-1 receptor agonists; Cr: Creatinine; UA: Uric acid; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TBil: Total bilirubin; OS: Osteocalcin;  $\beta$ -CTX:  $\beta$ -collagen special sequence; TP1NP: Total type I procollagen N-terminal extension peptide; DXA: Dual energy X-ray absorptiometry; LS-BMD: Lumbar spine (L1-L4) bone mineral density; FN-BMD: Femoral neck bone mineral density; H-BMD: Hip bone mineral density; T-BMD: Total (whole-body) bone mineral density; ASMI: Appendicular skeletal muscle index.

**Table 4 Comparison of baseline characteristics among older type 2 diabetes mellitus patients**

Characteristics	Total (n = 470)	GNRI tertile 1 (n = 167)	GNRI tertile 2 (n = 162)	GNRI tertile 3 (n = 141)	F/H/ $\chi^2$	P value
Women [n (%)]	184 (39.1)	69 (41.3)	63 (38.9)	52 (36.9)	0.636	0.425
Age (yr)	61.12 ± 7.25	62.6 ± 7.56	61.43 ± 7.01	59.02 ± 6.70	18.962	< 0.001
Height (cm)	166.69 ± 8.1	165.5 ± 7.80	167.1 ± 8.55	167.62 ± 7.79	5.425	0.020
Weight (kg)	70.00 (62.00-80.00)	62.00 (57.00-70.00)	72.50 (65.00-80.00)	80.00 (72.00-85.50)	12.768	< 0.001
Diabetes duration (yr)	8.68 ± 6.62	10.13 ± 6.79	8.74 ± 6.90	6.89 ± 5.62	18.945	< 0.001
BMI (kg/m <sup>2</sup> )	25.39 (23.32-27.55)	23.05 (21.34-24.57)	25.71 (24.33-27.11)	28.01 (26.51-29.75)	15.296	< 0.001
SBP (mmHg)	136.16 ± 15.49	135.35 ± 17.25	138.2 ± 15.13	134.78 ± 13.42	0.049	0.825
DBP (mmHg)	80.65 ± 9.75	79.15 ± 10.12	81.93 ± 9.93	80.96 ± 8.86	2.998	0.084
Hypertension [n (%)]	267 (56.8)	95 (56.9)	96 (59.3)	76 (53.9)	0.237	0.626
GNRI (score)	105.09 (98.93-110.98)	97.09 (93.08-99.55)	105.57 (103.59-107.63)	113.94 (111.77-118.57)	22.930	< 0.001
<b>Glucose-lowering therapies [n (%)]</b>						
Lifestyle alone	63 (13.4)	17 (10.2)	24 (14.8)	22 (15.6)	2.019	0.155
Insulin treatments	175 (37.2)	74 (44.3)	59 (36.4)	42 (29.8)	6.938	0.008
Insulin secretagogues	178 (37.9)	71 (42.5)	60 (37.0)	47 (33.3)	2.771	0.096
Insulin sensitizers	59 (12.6)	19 (11.4)	22 (13.6)	18 (12.8)	0.152	0.697

Metformin	230 (48.9)	68 (40.7)	79 (48.8)	83 (58.9)	10.012	0.002
AGIs	76 (16.2)	17 (10.2)	26 (16.0)	33 (23.4)	9.802	0.002
DPP-4Is	38 (8.1)	14 (8.4)	14 (8.6)	10 (7.1)	0.158	0.691
SGLT-2Is	67 (14.3)	17 (10.2)	27 (16.7)	23 (16.3)	2.509	0.113
GLP-1RAs	26 (5.5)	3 (1.8)	9 (5.6)	14 (9.9)	9.636	0.002
Statins	84 (17.9)	25 (15.0)	33 (20.4)	26 (18.4)	0.707	0.400
<b>Laboratory findings</b>						
HbA1c (%)	8.98 ± 1.82	9.47 ± 1.93	8.86 ± 1.61	8.54 ± 1.79	21.198	< 0.001
Albumin (g/L)	38.25 (35.8-41)	35.80 (33.50-37.30)	38.40 (36.70-40.60)	41.70 (39.70-44.00)	15.071	< 0.001
Cr (μmol/L)	61.5 ± 23.74	61.93 ± 27.54	60.59 ± 24.35	62.03 ± 17.46	0.000	0.994
UA (μmol/L)	310.35 ± 92.39	282.96 ± 85.27	314.1 ± 89.47	338.47 ± 95.18	29.509	< 0.001
TG (mmol/L)	1.78 (1.15-2.87)	1.42 (0.97-2.44)	1.75 (1.18-2.62)	2.29 (1.41-3.83)	5.347	< 0.001
TC (mmol/L)	4.37 ± 1.04	4.27 ± 1.04	4.34 ± 1.03	4.53 ± 1.04	4.991	0.026
HDL-C (mmol/L)	1.16 ± 0.27	1.15 ± 0.29	1.18 ± 0.26	1.13 ± 0.27	0.348	0.555
LDL-C (mmol/L)	2.79 ± 0.87	2.75 ± 0.87	2.77 ± 0.84	2.87 ± 0.9	1.525	0.218
TBil (μmol/L)	11.31 ± 4.89	10.43 ± 4.91	11.56 ± 4.89	12.06 ± 4.75	8.890	0.003
OS (ng/mL)	11.81 ± 4.23	12.07 ± 4.63	11.93 ± 4.19	11.37 ± 3.76	1.992	0.159
β-CTX (ng/mL)	0.45 ± 0.23	0.5 ± 0.25	0.44 ± 0.22	0.39 ± 0.18	22.076	< 0.001
TP1NP (ng/mL)	40.34 ± 14.84	40.65 ± 14.83	40.96 ± 15.33	39.26 ± 14.33	0.617	0.433
<b>DXA parameters (g/cm<sup>2</sup>)</b>						
LS-BMD	0.95 ± 0.16	0.91 ± 0.15	0.98 ± 0.18	0.97 ± 0.14	12.015	0.001
FN-BMD	0.75 ± 0.12	0.71 ± 0.11	0.77 ± 0.13	0.78 ± 0.10	29.138	< 0.001
H-BMD	0.89 ± 0.13	0.84 ± 0.12	0.9 ± 0.14	0.93 ± 0.11	45.242	< 0.001
T-BMD	1.08 ± 0.12	1.06 ± 0.12	1.09 ± 0.13	1.1 ± 0.11	10.818	0.001
<b>Body composition</b>						
Total body fat (%)	30.69 ± 6.68	28.72 ± 6.83	30.62 ± 5.81	33.09 ± 6.71	34.740	< 0.001
Android/gynoid ratio	1.31 ± 0.21	1.24 ± 0.22	1.33 ± 0.21	1.36 ± 0.19	28.386	< 0.001
Fat mass index (kg/m <sup>2</sup> )	7.32 (6.17-8.99)	6.26 (4.97-7.51)	7.38 (6.42-8.59)	8.70 (7.20-10.56)	10.212	< 0.001
Lean mass index (kg/m <sup>2</sup> )	16.94 (15.56-18.51)	15.82 (14.71-17.03)	17.17 (15.92-18.43)	18.56 (16.77-19.81)	10.488	< 0.001
ASMI (kg/m <sup>2</sup> )	7.02 ± 1.09	6.44 ± 0.91	7.09 ± 0.97	7.63 ± 1.08	112.733	< 0.001

BMI: Body mass index; SBP: Systolic/diastolic blood pressure; DBP: Diastolic blood pressure; GNRI: Geriatric nutritional risk index; AGIs:  $\alpha$ -glucosidase inhibitors; DPP-4Is: Dipeptidyl peptidase-4 inhibitors; SGLT-2Is: Sodium-glucose cotransporter-2 inhibitors; GLP-1RAs: Glucagon-like peptide-1 receptor agonists; Cr: Creatinine; UA: Uric acid; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; TBil: Total bilirubin; OS: Osteocalcin;  $\beta$ -CTX:  $\beta$ -collagen special sequence; TP1NP: Total type I procollagen N-terminal extension peptide; DXA: Dual energy X-ray absorptiometry; LS-BMD: Lumbar spine (L1-L4) bone mineral density; FN-BMD: Femoral neck bone mineral density; H-BMD: Hip bone mineral density; T-BMD: Total (whole-body) bone mineral density; ASMI: Appendicular skeletal muscle index.

**Table 5 Multiple linear regression models displaying associations of the Geriatric Nutritional Risk Index with bone mineral density**

Models	B (95%CI)	$\beta$	t value	P value	Adjusted R <sup>2</sup> for model
<b>Lumbar spine BMD</b>					
Model 0 <sup>1</sup>	0.003 (0.002 to 0.004)	0.186	4.952	< 0.001	0.033
Model 1 <sup>2</sup>	-0.002 (-0.004 to 0.000)	-0.113	-1.919	0.055	0.150
Model 2 <sup>3</sup>	-0.002 (-0.004 to 0.000)	-0.105	-1.765	0.078	0.153

Model 3 <sup>4</sup>	0.040 (0.008 to 0.071)	2.402	2.492	0.013	0.197
<b>Femoral neck BMD</b>					
Model 0 <sup>1</sup>	0.004 (0.003 to 0.005)	0.281	7.664	< 0.001	0.077
Model 1 <sup>2</sup>	-0.001 (-0.002 to 0.000)	-0.071	-1.32	0.187	0.293
Model 2 <sup>3</sup>	-0.001 (-0.002 to 0.000)	-0.06	-1.12	0.263	0.306
Model 3 <sup>4</sup>	0.027 (0.004 to 0.049)	2.047	2.345	0.019	0.341
<b>Total hip BMD</b>					
Model 0 <sup>1</sup>	0.005 (0.004 to 0.006)	0.363	10.213	< 0.001	0.131
Model 1 <sup>2</sup>	0.000 (-0.002 to 0.001)	-0.034	-0.636	0.525	0.312
Model 2 <sup>3</sup>	0.000 (-0.002 to 0.001)	-0.025	-0.477	0.634	0.318
Model 3 <sup>4</sup>	0.021 (-0.003 to 0.044)	1.52	1.745	0.082	0.343

<sup>1</sup>Unadjusted model.

<sup>2</sup>Adjusted for age, sex, diabetes duration, hypertension, SBP, DBP, and BMI.

<sup>3</sup>Additionally adjusted for antidiabetic treatments and statin medications.

<sup>4</sup>Additionally adjusted for HbA1c, Osteocalcin,  $\beta$ -collagen special sequence, total type I procollagen N-terminal extension peptide, albumin, Creatinine, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total bilirubin.

95%CI: 95% confidence interval; BMD: Bone mineral density.

**Table 6 Determinants of bone mineral density using multivariate forward linear regression analysis**

Factors	B	SE	t value	P value	95%CI	
					Lower	Upper
Lumbar spine BMD						
Age	-0.002	0.001	-3.754	< 0.001	-0.003	-0.001
Height	0.003	0.001	3.669	< 0.001	0.001	0.005
Diabetes duration	-0.003	0.001	-2.665	0.008	-0.005	-0.001
Albumin	-0.004	0.001	-2.864	0.004	-0.007	-0.001
Cr	0.001	0.000	1.983	0.048	0.000	0.001
β-CTX	-0.089	0.033	-2.724	0.007	-0.153	-0.025
TP1NP	-0.001	0.000	-1.633	0.103	-0.002	0.000
ASMI	-0.040	0.016	-2.449	0.015	-0.072	-0.008
Lean mass index	0.036	0.008	4.498	< 0.001	0.020	0.051
Femoral neck BMD						
Age	-0.003	0	-6.8	< 0.001	-0.003	-0.002
Height	0.003	0.001	4.672	< 0.001	0.002	0.004
Diabetes duration	-0.002	0.001	-3.617	< 0.001	-0.004	-0.001
Albumin	-0.003	0.001	-2.698	0.007	-0.005	-0.001
β-CTX	-0.100	0.018	-5.589	< 0.001	-0.135	-0.065
Android/gynoid ratio	-0.045	0.02	-2.259	0.024	-0.084	-0.006
ASMI	0.011	0.012	0.963	0.336	-0.012	0.034
Lean mass index	0.014	0.006	2.457	0.014	0.003	0.025
Total hip BMD						
Age	-0.002	0.000	-5.451	< 0.001	-0.003	-0.001
Weight	0.002	0.001	3.142	0.002	0.001	0.003
Diabetes duration	-0.002	0.001	-3.327	0.001	-0.004	-0.001

$\beta$ -CTX	-0.082	0.019	-4.403	< 0.001	-0.118	-0.045
Android/gynoid ratio	-0.041	0.02	-2.003	0.046	-0.081	-0.001
Lean mass index	0.020	0.003	6.266	< 0.001	0.014	0.026

95%CI: 95% confidence interval; BMD: Bone mineral density; Cr: Creatinine;  $\beta$ -CTX:  $\beta$ -collagen special sequence; TP1NP: Total type I procollagen N-terminal extension peptide; ASMI: Appendicular skeletal muscle index.

**Table 7 Determinants of appendicular skeletal muscle index using multivariate forward linear regression analysis**

Factors	B	SE	t value	P value	95%CI	
					Lower	Upper
Men						
Age	-0.012	0.003	-3.721	< 0.001	-0.019	-0.006
Weight	0.019	0.006	2.983	0.003	0.006	0.031
Diabetes duration	-0.014	0.005	-2.587	0.010	-0.025	-0.003
BMI	0.136	0.022	6.238	< 0.001	0.093	0.178
HbA1c	-0.057	0.017	-3.449	0.001	-0.090	-0.025
Women						
Age	-0.008	0.003	-2.811	0.005	-0.014	-0.003
Weight	0.066	0.003	20.846	< 0.001	0.059	0.072
Height	-0.030	0.007	-4.491	< 0.001	-0.043	-0.017
TBil	-0.017	0.007	-2.369	0.018	-0.032	-0.003
OS	0.019	0.009	2.147	0.033	0.002	0.037
β-CTX	-0.536	0.175	-3.059	0.002	-0.881	-0.191

95%CI: 95% confidence interval; BMI: Body mass index; TBil: Total bilirubin; OS: Osteocalcin;  $\beta$ -CTX:  $\beta$ -collagen special sequence.

an increased risk of low muscle mass *via* a variety of mechanisms. The main causes include insulin resistance, inflammation, and the production of glycation end products. Therefore, nutritional balance is beneficial to control blood sugar and reduce the incidence of sarcopenia. Individuals with type 2 diabetes, especially the elderly, need individualized dietary strategies to reduce the incidence of malnutrition. Regular nutritional assessments are necessary. People with type 2 diabetes can avoid the adverse effects of malnutrition by adjusting their diet.

At all bone sites, there was a correlation between low BMD and a high level of  $\beta$ -CTX, which is the third significant discovery of this research.  $\beta$ -CTX is derived from the degradation of type I collagen, and its content in bone collagen is much higher than that in the rest of the tissue, so it can be more representative and more directly reflect the degradation of bone matrix collagen and be used as an indicator of bone resorption. Bone homeostasis depends on the resorption and formation of bones. Long-term hyperglycemia can affect the adhesion of osteoblasts to collagen, causing dysfunction of osteoblasts, inhibiting bone formation and accelerating bone resorption, causing an increase in PINP and  $\beta$ -CTX. This may explain our finding of an association between a high  $\beta$ -CTX level and low BMD.  $\beta$ -CTX plays a critical role in bone turnover and is a sensitive marker for the early diagnosis of osteoporosis.

Another important finding of this study is that age was negatively correlated with ASMI. Sarcopenia is the age-related loss of muscle mass, strength, and function[28]. Degenerative changes in the structure and function of the human neuromuscular system occur with age, and the presence of diabetes accelerates the decline in muscle mass and strength through changes such as high levels of reactive oxygen species produced by oxidative stress and dysfunctional mitochondria. In this study, we also found a significant association between weight and ASMI. The majority of studies have shown that low BMI is also associated with sarcopenia[29]. Malnutrition, a potent risk factor for sarcopenia, could potentially account for the higher occurrence and frequency of sarcopenia in individuals with reduced body weight. Malnutrition, a potent risk factor for sarcopenia, might well explain the increased prevalence and incidence of sarcopenia in individuals with lower weight.

This study had multiple limitations. Because the study had a cross-sectional design, it was not possible to establish causal relationships. Furthermore, the participants chosen for this research encompassed both males and females spanning a wide age bracket of 21 to 81 years. T2DM patients of the same gender and age range have not been studied, but this study is closer to the clinical situation. Also, we only included participants who were hospitalized; we did not evaluate muscle strength and quality. In the end, although we did not consider that environmental pollutants (mainly air

pollutants) is able to significantly affect both the clinical features of T2DM (mainly onset of disease and blood sugar control) and the nutritional status, we selected participants who lived in the same area for a long time. In the future, we will consider selecting participants from different regions of China for further research.

## CONCLUSION

Poor nutrition, as indicated by a low GNRI, was associated with low levels of ASMI and BMD at all bone sites in T2DM patients. Using the GNRI to evaluate nutritional status and using DXA to investigate body composition in patients with T2DM is of value in assessing bone health and physical performance.

## ARTICLE HIGHLIGHTS

### Research background

In people with type 2 diabetes mellitus (T2DM), the association between nutrition, sarcopenia, and osteoporosis has rarely been explored.

### Research motivation

The relationship between nutritional status and bone mass has been observed in different populations, including individuals with chronic obstructive pulmonary disease, rheumatoid arthritis, and end-stage renal disease.

### Research objectives

Assess the associations among nutrition, bone mineral density (BMD) and body composition in patients with T2DM.

### Research methods

A total of 689 patients with T2DM were included to perform a retrospective analysis. The general information and biochemical indices of these patients were statistically analyzed.

### Research results

Those who had a high Geriatric Nutritional Risk Index (GNRI) tended to be younger and had lower HbA1c, higher BMD at all bone sites, and higher appendicular skeletal muscle index.

### Research conclusions

Poor nutrition, as indicated by a low GNRI, was associated with low levels of ASMI and BMD at all bone sites in type 2 diabetes mellitus patients.

### Research perspectives

We used a retrospective study to explore the association between nutrition, sarcopenia, and osteoporosis in patients with T2DM.

## FOOTNOTES

**Author contributions:** Zhu XX and Wang LH designed the research; Zhu XX and Yao KF collected the data; Zhu XX and Huang HY analyzed the data; Zhu XX and Yao KF wrote the paper; Wang LH reviewed the paper.

**Supported by** Social Development Projects of Nantong, No. MS22021008 and No. QNZ2022005.

**Institutional review board statement:** The study was approved by the institutional review board of The Second Affiliated Hospital of Nantong University, First People's Hospital of Nantong City (approval number: 2021KT063).

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** All the Authors have no conflict of interest related to the manuscript.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers.



It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

**Country/Territory of origin:** China

**ORCID number:** Li-Hua Wang [0000-0001-5783-6317](https://orcid.org/0000-0001-5783-6317).

**S-Editor:** Lin C

**L-Editor:** A

**P-Editor:** Yuan YY

## REFERENCES

- 1 Yin L, Xu Z, Wang L, Li W, Zhao Y, Su Y, Sun W, Liu Y, Yang M, Yu A, Blake GM, Wu X, Veldhuis-Vlug AG, Cheng X, Hind K, Engelke K. Associations of Muscle Size and Density With Proximal Femur Bone in a Community Dwelling Older Population. *Front Endocrinol (Lausanne)* 2020; **11**: 503 [PMID: [32849289](https://pubmed.ncbi.nlm.nih.gov/32849289/) DOI: [10.3389/fendo.2020.00503](https://doi.org/10.3389/fendo.2020.00503)]
- 2 Miyamoto K, Hirayama A, Sato Y, Ikeda S, Maruyama M, Soga T, Tomita M, Nakamura M, Matsumoto M, Yoshimura N, Miyamoto T. A Metabolomic Profile Predictive of New Osteoporosis or Sarcopenia Development. *Metabolites* 2021; **11** [PMID: [33924750](https://pubmed.ncbi.nlm.nih.gov/33924750/) DOI: [10.3390/metabo11050278](https://doi.org/10.3390/metabo11050278)]
- 3 Liu X, Wang L, Xing Y, Engel SS, Zeng L, Yao B, Xu W, Chen G, Zhang Y, Zhang R, Liu S, Weng J, Ji Q. Efficacy and safety of metformin and sitagliptin-based dual and triple therapy in elderly Chinese patients with type 2 diabetes: Subgroup analysis of STRATEGY study. *J Diabetes Investig* 2020; **11**: 1532-1541 [PMID: [32304283](https://pubmed.ncbi.nlm.nih.gov/32304283/) DOI: [10.1111/jdi.13277](https://doi.org/10.1111/jdi.13277)]
- 4 Yamamoto M. Insights into bone fragility in diabetes: the crucial role of bone quality on skeletal strength. *Endocr J* 2015; **62**: 299-308 [PMID: [25797364](https://pubmed.ncbi.nlm.nih.gov/25797364/) DOI: [10.1507/endocrj.EJ15-0129](https://doi.org/10.1507/endocrj.EJ15-0129)]
- 5 Bitar MS, Nader J, Al-Ali W, Al Madhoun A, Arefanian H, Al-Mulla F. Hydrogen Sulfide Donor NaHS Improves Metabolism and Reduces Muscle Atrophy in Type 2 Diabetes: Implication for Understanding Sarcopenic Pathophysiology. *Oxid Med Cell Longev* 2018; **2018**: 6825452 [PMID: [30510624](https://pubmed.ncbi.nlm.nih.gov/30510624/) DOI: [10.1155/2018/6825452](https://doi.org/10.1155/2018/6825452)]
- 6 Wang T, Feng X, Zhou J, Gong H, Xia S, Wei Q, Hu X, Tao R, Li L, Qian F, Yu L. Type 2 diabetes mellitus is associated with increased risks of sarcopenia and pre-sarcopenia in Chinese elderly. *Sci Rep* 2016; **6**: 38937 [PMID: [27958337](https://pubmed.ncbi.nlm.nih.gov/27958337/) DOI: [10.1038/srep38937](https://doi.org/10.1038/srep38937)]
- 7 Izzo A, Massimino E, Riccardi G, Della Pepa G. A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors. *Nutrients* 2021; **13** [PMID: [33435310](https://pubmed.ncbi.nlm.nih.gov/33435310/) DOI: [10.3390/nu13010183](https://doi.org/10.3390/nu13010183)]
- 8 Murata Y, Kadoya Y, Yamada S, Sanke T. Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors. *Diabetol Int* 2018; **9**: 136-142 [PMID: [30603361](https://pubmed.ncbi.nlm.nih.gov/30603361/) DOI: [10.1007/s13340-017-0339-6](https://doi.org/10.1007/s13340-017-0339-6)]
- 9 Ono Y, Miyakoshi N, Kasukawa Y, Akagawa M, Kimura R, Nagahata I, Yuasa Y, Sato C, Shimada Y. Diagnosis of Presarcopenia Using Body Height and Arm Span for Postmenopausal Osteoporosis. *Clin Interv Aging* 2020; **15**: 357-361 [PMID: [32210546](https://pubmed.ncbi.nlm.nih.gov/32210546/) DOI: [10.2147/CIA.S231759](https://doi.org/10.2147/CIA.S231759)]
- 10 Chen HL, Deng LL, Li JF. Prevalence of Osteoporosis and Its Associated Factors among Older Men with Type 2 Diabetes. *Int J Endocrinol* 2013; **2013**: 285729 [PMID: [23401682](https://pubmed.ncbi.nlm.nih.gov/23401682/) DOI: [10.1155/2013/285729](https://doi.org/10.1155/2013/285729)]
- 11 Xiu S, Chhetri JK, Sun L, Mu Z, Wang L. Association of serum prealbumin with risk of osteoporosis in older adults with type 2 diabetes mellitus: a cross-sectional study. *Ther Adv Chronic Dis* 2019; **10**: 2040622319857361 [PMID: [31223465](https://pubmed.ncbi.nlm.nih.gov/31223465/) DOI: [10.1177/2040622319857361](https://doi.org/10.1177/2040622319857361)]
- 12 Umpierrez GE, Pasquel FJ. Management of Inpatient Hyperglycemia and Diabetes in Older Adults. *Diabetes Care* 2017; **40**: 509-517 [PMID: [28325798](https://pubmed.ncbi.nlm.nih.gov/28325798/) DOI: [10.2337/dc16-0989](https://doi.org/10.2337/dc16-0989)]
- 13 Ferguson M, Capra S, Bauer J, Banks M. Development of a valid and reliable malnutrition screening tool for adult acute hospital patients. *Nutrition* 1999; **15**: 458-464 [PMID: [10378201](https://pubmed.ncbi.nlm.nih.gov/10378201/) DOI: [10.1016/S0899-9007\(99\)00084-2](https://doi.org/10.1016/S0899-9007(99)00084-2)]
- 14 Stratton RJ, Hackston A, Longmore D, Dixon R, Price S, Stroud M, King C, Elia M. Malnutrition in hospital outpatients and inpatients: prevalence, concurrent validity and ease of use of the 'malnutrition universal screening tool' ('MUST') for adults. *Br J Nutr* 2004; **92**: 799-808 [PMID: [15533269](https://pubmed.ncbi.nlm.nih.gov/15533269/) DOI: [10.1079/BJN20041258](https://doi.org/10.1079/BJN20041258)]
- 15 Rubenstein LZ, Harker JO, Salvà A, Guigoz Y, Vellas B. Screening for undernutrition in geriatric practice: developing the short-form mini-nutritional assessment (MNA-SF). *J Gerontol A Biol Sci Med Sci* 2001; **56**: M366-M372 [PMID: [11382797](https://pubmed.ncbi.nlm.nih.gov/11382797/) DOI: [10.1093/gerona/56.6.M366](https://doi.org/10.1093/gerona/56.6.M366)]
- 16 Kondrup J, Rasmussen HH, Hamberg O, Stanga Z; Ad Hoc ESPEN Working Group. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. *Clin Nutr* 2003; **22**: 321-336 [PMID: [12765673](https://pubmed.ncbi.nlm.nih.gov/12765673/) DOI: [10.1016/S0261-5614\(02\)00214-5](https://doi.org/10.1016/S0261-5614(02)00214-5)]
- 17 Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. *Am J Clin Nutr* 2005; **82**: 777-783 [PMID: [16210706](https://pubmed.ncbi.nlm.nih.gov/16210706/) DOI: [10.1093/ajcn/82.4.777](https://doi.org/10.1093/ajcn/82.4.777)]
- 18 Lakhdar R, Rabinovich RA. Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease? *J Thorac Dis* 2018; **10**: S1377-S1389 [PMID: [29928520](https://pubmed.ncbi.nlm.nih.gov/29928520/) DOI: [10.21037/jtd.2018.05.81](https://doi.org/10.21037/jtd.2018.05.81)]
- 19 Reina D, Gómez-Vaquero C, Díaz-Torné C, Solé JMN; Rheumatology Service. Hospital Moisès Broggi. Assessment of nutritional status by dual X-Ray absorptiometry in women with rheumatoid arthritis: A case-control study. *Medicine (Baltimore)* 2019; **98**: e14361 [PMID: [30732168](https://pubmed.ncbi.nlm.nih.gov/30732168/) DOI: [10.1097/MD.00000000000014361](https://doi.org/10.1097/MD.00000000000014361)]
- 20 Tokumoto H, Tominaga H, Arishima Y, Jokoji G, Akimoto M, Ohtsubo H, Taketomi E, Sunahara N, Nagano S, Ishidou Y, Komiya S, Setoguchi T. Association between Bone Mineral Density of Femoral Neck and Geriatric Nutritional Risk Index in Rheumatoid Arthritis Patients Treated with Biological Disease-Modifying Anti-Rheumatic Drugs. *Nutrients* 2018; **10** [PMID: [29463015](https://pubmed.ncbi.nlm.nih.gov/29463015/) DOI: [10.3390/nu10020234](https://doi.org/10.3390/nu10020234)]
- 21 Nakanishi K, Shishido K, Kumata C, Ito K, Nakashima Y, Wakasa M. Bone density of the femoral neck in patients on maintenance dialysis. *PLoS One* 2018; **13**: e0197965 [PMID: [29795652](https://pubmed.ncbi.nlm.nih.gov/29795652/) DOI: [10.1371/journal.pone.0197965](https://doi.org/10.1371/journal.pone.0197965)]
- 22 Donnelly A. Nutritional requirements in malnutrition and diabetes mellitus. *Nurs Stand* 2018; **33**: 69-76 [PMID: [29873473](https://pubmed.ncbi.nlm.nih.gov/29873473/) DOI: [10.7748/ns.2018.e11169](https://doi.org/10.7748/ns.2018.e11169)]

- 23 **Wang L**, Zhang D, Xu J. Association between the Geriatric Nutritional Risk Index, bone mineral density and osteoporosis in type 2 diabetes patients. *J Diabetes Investig* 2020; **11**: 956-963 [PMID: [31828962](#) DOI: [10.1111/jdi.13196](#)]
- 24 **Bering T**, Diniz KGD, Coelho MPP, Vieira DA, Soares MMS, Kakehasi AM, Correia MITD, Teixeira R, Queiroz DMM, Rocha GA, Silva LD. Association between pre-sarcopenia, sarcopenia, and bone mineral density in patients with chronic hepatitis C. *J Cachexia Sarcopenia Muscle* 2018; **9**: 255-268 [PMID: [29349902](#) DOI: [10.1002/jcsm.12269](#)]
- 25 **Chiu TH**, Chen SC, Yu HC, Hsu JS, Shih MC, Jiang HJ, Hsu WH, Lee MY. Association between Geriatric Nutrition Risk Index and Skeletal Muscle Mass Index with Bone Mineral Density in Post-Menopausal Women Who Have Undergone Total Thyroidectomy. *Nutrients* 2020; **12** [PMID: [32516885](#) DOI: [10.3390/nu12061683](#)]
- 26 **Chen SC**, Chung WS, Wu PY, Huang JC, Chiu YW, Chang JM, Chen HC. Associations among Geriatric Nutrition Risk Index, bone mineral density, body composition and handgrip strength in patients receiving hemodialysis. *Nutrition* 2019; **65**: 6-12 [PMID: [31029923](#) DOI: [10.1016/j.nut.2019.02.013](#)]
- 27 **Fang L**, Zhong S, Ma D, Li C, Hao Y, Gao Y, Zhang L, Shen L. A cross-sectional study: an assessment of low muscle mass and osteoporosis in type 2 diabetes mellitus patients with a high glycated hemoglobin level. *Ther Adv Chronic Dis* 2021; **12**: 20406223211026762 [PMID: [34262679](#) DOI: [10.1177/20406223211026762](#)]
- 28 **Rotini A**, Martínez-Sarrà E, Duelen R, Costamagna D, Di Filippo ES, Giacomazzi G, Grosemans H, Fulle S, Sampaolesi M. Aging affects the in vivo regenerative potential of human mesoangioblasts. *Aging Cell* 2018; **17** [PMID: [29397577](#) DOI: [10.1111/accel.12714](#)]
- 29 **Choi CJ**, Choi WS, Kim CM, Lee SY, Kim KS. Risk of Sarcopenia and Osteoporosis in Male Tuberculosis Survivors: Korea National Health and Nutrition Examination Survey. *Sci Rep* 2017; **7**: 13127 [PMID: [29030560](#) DOI: [10.1038/s41598-017-12419-y](#)]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

